Mirror Site, please visit our main site www.timtec.com

Text Size
Home Company News and Articles Articles The Effect of Freeze/Thaw Cycles on the Stability of Compounds in DMSO

News and Articles

The Effect of Freeze/Thaw Cycles on the Stability of Compounds in DMSO

  • Print
Abstract: A diverse set of 320 compounds from the Procter & Gamble Pharmaceuticals organic compound repository was prepared as 20-mM DMSO solutions and stored at 4°C under argon in pressurized canisters to simulate a low-humidity environment.

The plates were subjected to 25 freeze/thaw cycles while being exposed to ambient atmospheric conditions after each thaw to simulate the time and manner by which compound plates are exposed to the atmosphere during typical liquid-handling and high-throughput screening processes.

High-performance liquid chromatography-mass spectrometry with evaporative light-scattering detection was used to quantitate the amount of compound remaining after every 5th freeze/thaw cycle. Control plates were stored either at room temperature under argon or at 4°C under argon without freeze/thaw cycling and were evaluated at the midpoint and the endpoint of the study. The study was conducted over a short time period (i.e., 7 weeks) to minimize the effect of compound degradation over time due to the exposure of the compounds to DMSO. The results from this study will be used to determine the maximum number of freeze/thaw cycles that can be achieved while maintaining acceptable compound integrity.

Author(s): Barbara A. Kozikowski ; Thomas M. Burt ; Debra A. Tirey ; Lisa E. Williams ; Barbara R. Kuzmak ; David T. Stanton ; Kenneth L. Morand ; Sandra L. Nelson
Source: Journal of Biomolecular Screening Volume: 8 Number: 2 Page: 210 -- 215

 

Related Most Recent Findings and Publications

Latest compound stability study rebuttals with the following:

“It is likely that a combination of low concentration and limited water uptake will help to minimize sample degradation and precipitation from solution. ¶ Our studies also showed that freeze-thawing is not correlated with sample stability. These last findings are in contrast to previous studies, where we believe that the reported sample instability may have been due to water uptake rather than freeze-thawing.”

Engeloch C., et. al. Stability of Screening Compounds in Wet DMSO. J Biomol Screening (2008), Vol. 13, No. 10, 999-1006.

Read More

 

Category: Articles

Database Access

Download SDF Files

Contact Us

P: 302-292-8500
F: 302-292-8520
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

eStore Product Search

IUPAC, Smiles, ID, MW, Name, CAS, MDL

Follow Us Message Us Friend Us Friend Us

eChemShop Chemicals, Equipment, Software

ChemDBsoft Chemical Database Software

Drug Discovery News

  • Osiris Wins Race to Market a Stem Cell Product with Canadian Go-Ahead

    Osiris Therapeutics’ adult stem cell therapy Prochymal® received approval from Health Canada for the treatment of acute graft-vs-host disease (GvHD) in children who failed to respond to steroids. The company will have to carry out certain post-launch confirmatory studies. The decision gives Osiris the distinction of being the first company to win full marketing approval [...]

  • Google Search Engine Forms Basis of Algorithm to Identify Prognostic Cancer Biomarkers

    Scientists have adapted the algorithm used by Google’s web search engine to develop a computational program that can identify panels of biomarkers for cancer prognosis. Google’s PageRank algorithm takes into account the network of hyperlinks between web documents as well as the search terms themselves to determine which pages are most relevant to a particular [...]

  • Janssen Reports Positive Phase III Data for Chronic Diabetic Peripheral Neuropathy Analgesic

    Janssen Pharmaceuticals reported Phase III results demonstrating the efficacy of Nucynta® ER (extended release tapentadol) in managing pain associated with chronic diabetic peripheral neuropathy (DPN). Janssen says the data is consistent with that of a separate study reported in 2011 in patients with DPN. Nucynta ER is a centrally acting analgesic that acts as both [...]

  • Ruga Licenses Selexagen’s RAF Kinase Program for Targeted Cancer Therapy

    Targeted cancer drug developer Ruga negotiated rights to Selexagen Therapeutics’ RAF kinase program. The firm claims the acquired technology addresses the drawbacks to BRAF inhibition as an approach to cancer therapy. Data has demonstrated that BRAF inhibition can actually induce adaptation in RAS-activated cells and promote the development of secondary skin lesions and RAS-mutated tumor [...]

  • Solvo, XenoBiotic to Provide In Vitro Transporter Services in the U.S.

    XenoBiotic Laboratories established a partnership with Hungary-based Solvo Biotechnology to offer in vitro transporter services in the U.S. Solvo will transfer its efflux and uptake transporter assays to XBL’s research facilities in New Jersey. The services will be made available to American customers through both Solvo and XBL sales channels. Through this collaboration Solvo will [...]

  • Affymetrix Launches Circulating Tumor Cell Platform in Deal with ScreenCell

    Affymetrix signed a worldwide distribution agreement for ScreenCell’s isolation devices and dilution buffers for the collection of circulating tumor cells (CTCs) in peripheral blood. The QuantiGene® ViewRNA CTC platform, which consists of ScreenCell’s products and Affymetrix’ QuantiGene ViewRNA Assays, is now available from Affymetrix. The arrangement makes Affymetrix the exclusive distributor of ScreenCell products used [...]

  • Alga Provides Feasible Mass Production System for Subunit Malaria Vaccine Candidate

    An algal system for manufacturing recombinant proteins has provided scientists with the means to generate a malaria-blocking vaccine candidate based on two native unglycosylated Plasmodium falciparum surface proteins, Pfs25 and Pfs28. The University of California, San Diego researchers produced the two P. falciparum proteins in the chloroplasts of the widely used model alga Chlamydomonas reinhardtii, [...]

  • Agilent Acquires Cancer In Vitro Diagnostic Firm Dako for $2.2B in Cash

    Agilent is buying Danish cancer in vitro diagnostics firm Dako for $2.2 billion in cash on a debt-free basis. Agilent says the acquisition is the largest in its history, and will complement its existing life science business and boost its presence in the clinical diagnostics market. “In the rapidly growing diagnostics market, Dako’s products and [...]

  • Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC

    Aveo Oncology and partner Astellas Pharma Europe reported positive data from the pivotal Phase III study Viro-1, comparing the once-daily oral tyrosine kinase inhibitor candidate tivozanib with sorafenib in 517 patients with advanced renal cell carcinoma (RCC). Astellas says it plans to submit a marketing authorization application for tivozanib to the European authorities during the [...]

  • Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool

    Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec reports that it [...]

    •